The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer

被引:5
|
作者
Erdogan, Mehmet [1 ]
Ozkan, Emine Elif [2 ]
Ozturk, Sefa Alperen [3 ]
Yildiz, Mustafa [1 ]
Sengul, Sevim Sureyya [1 ]
机构
[1] Suleyman Demirel Univ, Fac Med, Dept Nucl Med, Isparta, Turkey
[2] Suleyman Demirel Univ, Fac Med, Dept Radiat Oncol, Isparta, Turkey
[3] Suleyman Demirel Univ, Fac Med, Dept Urol, Isparta, Turkey
关键词
Ga-68 PSMA PET/CT; prostate cancer; oligometastasis; SUVmax; THERAPY; BIOLOGY;
D O I
10.4274/mirt.galenos.2020.89421
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives: In this study, we aimed to investigate whether Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) scanning is adequate to predict intermediate risk, high risk, or oligometastatic prostate cancer (PCa) as an initial staging modality. Methods: The Ga-68 PSMA PET/CT scan images of 50 PCa patients pathologically proven by transrectal ultrasound guided biopsy were evaluated retrospectively. The association of standard uptake value maximum (SUVmax) value of the area with the highest PSMA expression within the primary tumor with the risk groups and metastatic burden is investigated. Results: The SUVmax value was 6.18 in oligometastatic patients where it was measured as 10.93 in patients with higher metastatic burden (p=0.037). The cut-off SUVmax value for multiple metastases was 7.96 (p=0.047). According to the regression model, SUV max value has a positive influence [odds ratio (OR)=1.42], which was statistically significant (p=0.038). SUVmax values for intermediate and high risk patients were 6.91 and 11.44, respectively (p=0.014). The cut-off SUVmax value for the high risk group was 10.55 (p=0.006). In the regression model, SUV max value has a positive influence (OR=1.198), which was statistically significant (p=0.021). Conclusion: In this paper, we demonstrated the association between SUVmax value of primary tumor and Gleason score. Our results also allowed us to suggest that primary tumor SUVmax is a sufficiently accurate predictor of D'Amico risk groups in newly diagnosed PCa cases. Additionally, Ga-68 PSMA PET/CT turns out to be a useful tool in determiningoligometastatic PCa, which requires a different treatment approach.
引用
下载
收藏
页码:98 / 104
页数:7
相关论文
共 50 条
  • [41] The Importance Of Ga-68 PSMA PET CT In Detection Of Recurrence Metastasis Prostate Cancer Without Biochemical Recurrence
    Akgun, E.
    Sahin, O. E.
    Demirci, E.
    Akovali, B.
    Demirci, M. Ocak
    Aygun, A.
    Pehlivan, H.
    Karayel, E.
    Kural, A. R.
    Kabasakal, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S369 - S369
  • [42] Impact of Ga-68 HBED-CC PSMA PET/CT on therapeutic management of patients with prostate cancer
    Schreiter, Vera
    Schreiter, Nils
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [43] Complimentary role of 68Ga-GRPR PET/CT and 68GA-PSMA PET/CT in initial diagnosis of prostate cancer
    Gao, X.
    Tang, Y.
    Chen, M.
    Li, J.
    Yin, H.
    Gan, Y.
    Zu, X.
    Cai, Y.
    Hu, S.
    HISTOPATHOLOGY, 2022, 81 : 134 - 134
  • [44] Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue
    Krishnaraju, Venkata Subramanian
    Kumar, Rajender
    Mittal, Bhagwant Rai
    Sharma, Vishal
    Singh, Harjeet
    Nada, Ritambhra
    Bal, Amanjit
    Rohilla, Manish
    Singh, Harmandeep
    Rana, Surinder S.
    EUROPEAN RADIOLOGY, 2021, 31 (04) : 2199 - 2208
  • [45] Symmetric breasts metastatic prostate cancer shown by 68Ga-PSMA PET/CT scan
    Mokoala, Kgomotso
    Lawal, Ismaheel O.
    Lengana, Thabo
    Vorster, Mariza
    Sathekge, Mike M.
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2019, 22 (01): : 76 - 76
  • [46] Perineum and penile invasion of recurrent prostate carcinoma shown by Ga-68 PSMA PET/CT
    Koc, Zehra Pinar
    Ozcan, Pinar Pelin
    Ercolak, Vehbi
    INDIAN JOURNAL OF CANCER, 2021, 58 (01) : 101 - 103
  • [47] 68Ga-PSMA PET/CT in Preoperative Staging of Intermediate and High Risk Prostate Cancer Patients
    Schiller, C.
    Beheshti, M.
    Geinitz, H.
    Aschacher, B.
    Moinfar, F.
    Broinger, G.
    Pallwein-Prettner, L.
    Loidl, W.
    Langsteger, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S167 - S167
  • [48] 68 Ga-PSMA PET/CT for preoperative lymph nosde staging of high risk prostate cancer
    Schmautz, M.
    Heidenreich, A.
    Pfister, D.
    Hartmann, F.
    EUROPEAN UROLOGY, 2022, 81 : S985 - S985
  • [49] 68GA-PSMA PET/CT FOR PREOPERATIVE LYMPH NOSDE STAGING OF HIGH RISK PROSTATE CANCER
    Schmautz, Maximilian
    Pfister, David
    Hartmann, Florian
    Heidenreich, Axel
    JOURNAL OF UROLOGY, 2022, 207 (05): : E920 - E920
  • [50] The Role of Ga-68 PSMA PET / CT in Predicting Lu-177 PSMA Effectiveness: Can We Project the Ga-68 DOTA PET / CT and Lu-177 DOTA Treatment Experience to PSMA?
    Korkmaz, U.
    Soyluoglu, F. S.
    Durmus-Altun, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S468 - S468